Abstract: The present invention concerns compounds for use as a medicine having the formula the N-oxide forms, the salts, the quaternary amines and stereochemically isomeric forms thereof, wherein R1 represents hydrogen, C1-6alkyl, C1-4alkylthio, C1-4alkyloxy, or halo; R2 represents hydrogen or C1-6alkyl; R3 represents phenyl substituted with halo, cyano, C1-4alkyloxy, C1-4alkylthio, C1-6alkyl, haloC1-6alkyl; 2-thienyl; or 3-thienyl, R4 represents hydrogen; or R2 and R4 form an extra bond, which are active against dermatophytes, and their preparation; it further relates to compositions comprising them, as well as their use as a medicine.

Abstract: System, method and computer program product for recovering from a failure of a computing device. Start up of a first component of the device is monitored and a determination is made whether the first component has started successfully. If so, a second, higher level component of the device is started. Operational data received from the second component is monitored. If the operational data falls outside of an operational boundary, an action is performed on the second component to enable the second component to operate within a preferred operational boundary. If the first component does not start up successfully, a determination is made if start up of the first component is critical to operation of the second component. If so, a corrective action is performed relative to the first component and afterwards, an attempt is made to start up the second component.

Abstract: Compounds of formula (I) or a salt thereof are provided: wherein R6, R7, R9, R10, R11, X, n, p, Ar and m are as defined in the description. Uses of the compounds as medicaments, and in the manufacture of medicament for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder are also disclosed. The invention further discloses pharmaceutical compositions and combinations comprising the compounds.

Abstract: Novel acetophenone compounds of formula (I), compositions containing (I), processes for the preparation of (I), and use of (I) as inhibitors of the glycine transporter, are provided. Definitions of Ar, R5, R6, R7, R8 and n are provided in the specification.

Abstract: Compounds of formula (I) and salts and solvates are provided. Uses of the compounds as medicaments, and in the manufacture of medicament for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder are also disclosed. The invention further comprises processes to make these compounds and pharmaceutical formulations thereof.

Abstract: Compounds of formula (I) or a salt thereof are provided: wherein R1, R2, R3, R4, R5, R6, R7, R9, R10, X, n, p and m are as defined in the description. Uses of the compounds as medicaments, and in the manufacture of medicament for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder are also disclosed. The invention further discloses pharmaceutical compositions and combinations comprising the compounds.

Abstract: The invention provides a compound of formula (I) or a salt or solvate thereof: wherein R1, R2, R3, R4, R5, R6, R7, n, Het and Ar are as defined in the specification, and uses of such compounds. The compounds inhibit GlyT1 transporters and are useful in the treatment of certain neurological and neuropsychiatric disorders, including schizophrenia.

Abstract: The present invention relates to compounds of formula (I), or salts or solvates thereof, their use in the manufacture of medicaments for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder. The invention further comprises processes to make these compounds and pharmaceutical formulations thereof.

Abstract: The invention provides a compound of formula (I) or a salt or solvate thereof: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, n and Ar are as defined in the specification, and uses of such compounds. The compounds inhibit GlyT1 transporters and are useful in the treatment of certain neurological and neuropsychiatric disorders, including schizophrenia.

Abstract: The invention provides a compound of formula (I) or a salt or solvate thereof: wherein R, R1, R2, R3, R4, R5, R6, R7, R8, n and Ar are as defined in the specification, and uses of such compounds. The compounds inhibit GlyT1 transporters and are useful in the treatment of certain neurological and neuropsychiatric disorders, including schizophrenia.

Abstract: Demodulation apparatus for demodulating phase-modulated signals comprises a quadrature signal generator (QSG) for generating in-phase (I) and quadrature-phase (Q) signals in response to an unmodulated input signal. The QSG provides fast frequency tracking of the input signal and excludes any high-frequency content the input signal.

Abstract: A fibre-optic sensor package (10) comprises a serial array of fibre-optic sensing coils (14, 16, 18, 20, 22) each of which is comprised in a respective fibre-optic sensor. Four (14, 16, 18, 22) of the coils are housed in a protective casing (24). One of the coils (22) is comprised in a fibre-optic electromagnetic field sensor. The other coils are comprised in respective fibre-optic geophones and/or hydrophones. A single package of the invention allows detection of both seismic and electromagnetic signals. An array of packages of the invention provides detection of both seismic and electromagnetic signal at a series of positions over a long distance or wide area, thus avoiding the need for two conventional arrays. A packages of the invention, and an array of such packages, require little or no electrical power input.

Abstract: A fibre-optic sensor array (100) comprises a line array of fibre-optic sensor packages (AX, BX, CX, DX, AY, BY, CY, DY, AZ, BZ, CZ, DZ) each having a package input/output (i/o) fibre and each being arranged to output a finite output pulse series of optical output pulses via the package i/o fibre in response to input thereto of one or more interrogating optical pulses. The array further comprises a fibre-optic bus (104,106, 108, 110) extending along the length of the line array, each package i/o fibre being optically coupled to the fibre-optic bus at a respective positions along the line array. The array allows interrogation at a higher frequency than is the case for a serial array of the same number of fibre-optic sensing packages.

Abstract: Systems and methods for profiled and focused searching of litigation information allow a user to access specific legal information for use during litigation. The user can connect to a web site and access particular information from multiple sources based on the litigation task the user wishes to accomplish One litigation task is to create a litigation profile for a target, such as a particular litigant, attorney, judge, court, or firm. In this way, the user can perform focused and task-based searching to receive information about particular filings in particular locations, made by particular entities without knowing which sources contain certain pieces of the litigation information. For example, the user can receive all documents relating to summary judgment for patent infringement filed by a particular attorney in a particular court without specifying the source of information. In one aspect, the user can also access the source(s) upon receiving the results.

Abstract: Compounds of formula (I) and salts and solvates thereof are provided: wherein R1 to R8 and n are defined in the description. Uses of the compounds as medicaments, and in the manufacture of medicament for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder are also disclosed. The invention further comprises processes to make these compounds and pharmaceutical formulations thereof.

Abstract: Disclosed are N-aroyl cyclic amine derivatives having the formula: where the variables are as define herein, and their use as pharmaceuticals, specifically as orexin receptor antagonists.

Abstract: Disclosed are N-aroyl cyclic amine derivatives having the formula: where the variables are as define herein, and their use as pharmaceuticals, specifically as orexin receptor antagonists.

Abstract: Disclosed are N-aroyl cyclic amine derivatives having the formula: where the variables are as define herein, and their use as pharmaceuticals, specifically as orexin receptor antagonists.

Abstract: This invention relates to N-aroyl cyclic amine derivatives of formula (I), wherein X represents a bond, oxygen, NR3 or a group (CH2), wherein n represents 1, 2 or 3; Y represents CH2, CO, CH(OH), or CH2CH(OH); Het is an optionally substituted bicyclic heteroaryl group containing up to 4 heteroatoms selected from N, O and S; Ar2 represents an optionally substituted phenyl or a 5- or 6-membered heterocyclyl group containing up to 3 heteroatoms selected from N, O and S and their use as pharmaceuticals, specifically as orexin receptor antagonists.

Abstract: Disclosed are N-aroyl cyclic amine derivatives having the formula: where the variables are as define herein, and their use as pharmaceuticals, specifically as orexin receptor antagonists.